|
|
 |
xanodyne.com |
|
|
|
xanodyne.com |
| description: |
Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. We market a portfolio of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.. |
| keywords: |
Zipsor, Lysteda, Pain Management, Womens Health, Oramorph. |
| pain : 2.99 % Xanodyne : 2.56 % DuetDHA : 1.71 % ANNOUNCES : 1.71 % Zipsor : 1.71 % Oramorph : 1.71 % XANODYNE : 1.71 % management : 1.28 % market : 1.28 % prenatal : 1.28 % Product : 1.28 % prescription : 1.28 % vitamins : 1.28 % Pharmaceuticals : 1.28 % development : 1.28 % Inc : 1.28 % MORE : 1.28 % acute : 1.28 % Ferrazone : 0.85 % PLANNED : 0.85 % PRESIDENT : 0.85 % indicated : 0.85 % CEO : 0.85 % Company : 0.85 % NEWSROOM : 0.85 % PIPELINE : 0.85 % CAREERS : 0.85 % CONTACT : 0.85 % News : 0.85 % RENEWED : 0.85 % Announcements : 0.85 % PAIN : 0.85 % Recently : 0.85 % Developing : 0.85 % Approved : 0.85 % adults : 0.85 % mild : 0.85 % treatment : 0.85 % Highlights : 0.85 % PRODUCTS : 0.85 % MANAGEMENT : 0.85 % moderate : 0.85 % MARKET : 0.85 % Corporate : 0.85 % Welcome : 0.85 % Governance : 0.85 % FOCUS : 0.85 % SUCCESSION : 0.85 % advancing : 0.85 % line : 0.85 % company : 0.85 % late : 0.85 % stage : 0.85 % product : 0.85 % pipeline : 0.85 % ABOUT : 0.85 % both : 0.85 % focused : 0.85 % capabilities : 0.85 % commercial : 0.85 % integrated : 0.85 % portfolio : 0.85 % founded : 0.85 % pharmaceuticals : 0.85 % candidates : 0.85 % targeted : 0.85 % pharmaceutical : 0.85 % HOME : 0.85 % specialty : 0.85 % DIRECTIONS : 0.85 % PRIVACY : 0.85 % significant : 0.85 % markets : 0.85 % potential : 0.85 % morphine : 0.43 % than : 0.43 % release : 0.43 % patients : 0.43 % analgesia : 0.43 % more : 0.43 % opioid : 0.43 % require : 0.43 % few : 0.43 % who : 0.43 % tablet : 0.43 % fatty : 0.43 % key : 0.43 % amounts : 0.43 % minerals : 0.43 % designed : 0.43 % tolerated : 0.43 % well : 0.43 % right : 0.43 % provides : 0.43 % omega : 0.43 % enteric-coated : 0.43 % sustained : 0.43 % acids : 0.43 % that : 0.43 % vitamin : 0.43 % days : 0.43 % Phase : 0.43 % areas : 0.43 % Lysteda : 0.43 % focus : 0.43 % Xanodyne's : 0.43 % agrees : 0.43 % Withdrawal : 0.43 % Products : 0.43 % Withdraw : 0.43 % Womens : 0.43 % Health : 0.43 % Management : 0.43 % Pain : 0.43 % Voluntarily : 0.43 % withdraw : 0.43 % Propoxyphene : 0.43 % NSAID : 0.43 % capsule : 0.43 % ProSorb : 0.43 % technology : 0.43 % years : 0.43 % filled : 0.43 % liquid : 0.43 % women's : 0.43 % healthcare : 0.43 % approved : 0.43 % FDA : 0.43 % first : 0.43 % older : 0.43 % | XANODYNE ANNOUNCES : 1.63 % acute pain : 1.22 % Xanodyne Pharmaceuticals : 1.22 % pain management : 1.22 % Pharmaceuticals Inc : 1.22 % CONTACT US : 0.82 % Company News : 0.82 % US Company : 0.82 % News Announcements : 0.82 % PLANNED PRESIDENT : 0.82 % ANNOUNCES PLANNED : 0.82 % CAREERS CONTACT : 0.82 % PIPELINE NEWSROOM : 0.82 % DIRECTIONS ABOUT : 0.82 % PRIVACY DIRECTIONS : 0.82 % Recently Approved : 0.82 % ABOUT US : 0.82 % US PRODUCTS : 0.82 % PRESIDENT CEO : 0.82 % PRODUCTS PIPELINE : 0.82 % NEWSROOM CAREERS : 0.82 % ANNOUNCES RENEWED : 0.82 % pain adults : 0.82 % Welcome Xanodyne : 0.82 % Governance Welcome : 0.82 % moderate acute : 0.82 % mild moderate : 0.82 % DuetDHA DuetDHA : 0.82 % DuetDHA Ferrazone : 0.82 % Corporate Governance : 0.82 % MARKET Corporate : 0.82 % Product Highlights : 0.82 % SUCCESSION XANODYNE : 0.82 % RENEWED FOCUS : 0.82 % FOCUS PAIN : 0.82 % MANAGEMENT MARKET : 0.82 % PAIN MANAGEMENT : 0.82 % CEO SUCCESSION : 0.82 % HOME PRIVACY : 0.82 % market portfolio : 0.82 % focused pain : 0.82 % capabilities focused : 0.82 % portfolio prescription : 0.82 % prescription pharmaceuticals : 0.82 % prenatal vitamins : 0.82 % line prenatal : 0.82 % pharmaceuticals line : 0.82 % commercial capabilities : 0.82 % development commercial : 0.82 % integrated specialty : 0.82 % founded integrated : 0.82 % Inc founded : 0.82 % specialty pharmaceutical : 0.82 % pharmaceutical company : 0.82 % both development : 0.82 % company both : 0.82 % advancing late : 0.82 % vitamins advancing : 0.82 % product candidates : 0.82 % pipeline product : 0.82 % candidates targeted : 0.82 % targeted significant : 0.82 % Oramorph SR : 0.82 % potential markets : 0.82 % stage pipeline : 0.82 % significant potential : 0.82 % late stage : 0.82 % tablet indicated : 0.41 % SR Oramorph : 0.41 % MORE Oramorph : 0.41 % more than : 0.41 % patients who : 0.41 % morphine tablet : 0.41 % few days : 0.41 % than few : 0.41 % sustained release : 0.41 % release morphine : 0.41 % analgesia more : 0.41 % opioid analgesia : 0.41 % years or : 0.41 % require opioid : 0.41 % indicated pain : 0.41 % Oramorph sustained : 0.41 % adults years : 0.41 % indicated mild : 0.41 % or older : 0.41 % who require : 0.41 % pain patients : 0.41 % older MORE : 0.41 % right amounts : 0.41 % well tolerated : 0.41 % tolerated MORE : 0.41 % be well : 0.41 % designed be : 0.41 % vitamins minerals : 0.41 % minerals designed : 0.41 % MORE HOME : 0.41 % Announcements XANODYNE : 0.41 % Highlights Oramorph : 0.41 % SR DuetDHA : 0.41 % Developing Product : 0.41 % Approved Developing : 0.41 % Xanodyne Recently : 0.41 % key vitamins : 0.41 % amounts key : 0.41 % omega fatty : 0.41 % fatty acids : 0.41 % enteric-coated omega : 0.41 % Ferrazone enteric-coated : 0.41 % MORE DuetDHA : 0.41 % acids prescription : 0.41 % prescription prenatal : 0.41 % provides right : 0.41 % technology indicated : 0.41 % that provides : 0.41 % vitamin that : 0.41 % prenatal vitamin : 0.41 % days MORE : 0.41 % withdraw Propoxyphene : 0.41 % Voluntarily Withdraw : 0.41 % Withdraw Products : 0.41 % Inc Voluntarily : 0.41 % Announcements Xanodyne : 0.41 % Oramorph HOME : 0.41 % Products XANODYNE : 0.41 % Xanodyne Xanodyne : 0.41 % Product Withdrawal : 0.41 % Withdrawal Xanodyne : 0.41 % management Product : 0.41 % markets pain : 0.41 % management market : 0.41 % Health Oramorph : 0.41 % Womens Health : 0.41 % markets Xanodyne's : 0.41 % Xanodyne's focus : 0.41 % healthcare market : 0.41 % women's healthcare : 0.41 % management women's : 0.41 % focus areas : 0.41 % areas Zipsor : 0.41 % Management Womens : 0.41 % Pain Management : 0.41 % Lysteda Pain : 0.41 % Zipsor Lysteda : 0.41 % Xanodyne agrees : 0.41 % agrees withdraw : 0.41 % development Product : 0.41 % Highlights Zipsor : 0.41 % Phase development : 0.41 % pain Phase : 0.41 % treatment acute : 0.41 % Zipsor Zipsor : 0.41 % Zipsor first : 0.41 % capsule NSAID : 0.41 % NSAID ProSorb : 0.41 % filled capsule : 0.41 % liquid filled : 0.41 % first liquid : 0.41 % B treatment : 0.41 % XP B : 0.41 % Approved Zipsor : 0.41 % Zipsor treatment : 0.41 % market Recently : 0.41 % US market : 0.41 % Propoxyphene US : 0.41 % treatment mild : 0.41 % adults approved : 0.41 % Developing XP : 0.41 % FDA Developing : 0.41 % by FDA : 0.41 % approved by : 0.41 % ProSorb technology : 0.41 % | Xanodyne Pharmaceuticals Inc : 1.23 % MARKET Corporate Governance : 0.82 % Corporate Governance Welcome : 0.82 % MANAGEMENT MARKET Corporate : 0.82 % PAIN MANAGEMENT MARKET : 0.82 % FOCUS PAIN MANAGEMENT : 0.82 % Governance Welcome Xanodyne : 0.82 % acute pain adults : 0.82 % ANNOUNCES PLANNED PRESIDENT : 0.82 % significant potential markets : 0.82 % CEO SUCCESSION XANODYNE : 0.82 % XANODYNE ANNOUNCES PLANNED : 0.82 % moderate acute pain : 0.82 % mild moderate acute : 0.82 % HOME PRIVACY DIRECTIONS : 0.82 % PRIVACY DIRECTIONS ABOUT : 0.82 % US Company News : 0.82 % CONTACT US Company : 0.82 % Company News Announcements : 0.82 % RENEWED FOCUS PAIN : 0.82 % XANODYNE ANNOUNCES RENEWED : 0.82 % ANNOUNCES RENEWED FOCUS : 0.82 % CAREERS CONTACT US : 0.82 % NEWSROOM CAREERS CONTACT : 0.82 % ABOUT US PRODUCTS : 0.82 % DIRECTIONS ABOUT US : 0.82 % US PRODUCTS PIPELINE : 0.82 % PRODUCTS PIPELINE NEWSROOM : 0.82 % PIPELINE NEWSROOM CAREERS : 0.82 % targeted significant potential : 0.82 % candidates targeted significant : 0.82 % development commercial capabilities : 0.82 % both development commercial : 0.82 % commercial capabilities focused : 0.82 % capabilities focused pain : 0.82 % DuetDHA DuetDHA Ferrazone : 0.82 % focused pain management : 0.82 % company both development : 0.82 % pharmaceutical company both : 0.82 % Inc founded integrated : 0.82 % Pharmaceuticals Inc founded : 0.82 % founded integrated specialty : 0.82 % integrated specialty pharmaceutical : 0.82 % specialty pharmaceutical company : 0.82 % PRESIDENT CEO SUCCESSION : 0.82 % PLANNED PRESIDENT CEO : 0.82 % late stage pipeline : 0.82 % advancing late stage : 0.82 % stage pipeline product : 0.82 % pipeline product candidates : 0.82 % product candidates targeted : 0.82 % vitamins advancing late : 0.82 % prenatal vitamins advancing : 0.82 % portfolio prescription pharmaceuticals : 0.82 % market portfolio prescription : 0.82 % prescription pharmaceuticals line : 0.82 % pharmaceuticals line prenatal : 0.82 % line prenatal vitamins : 0.82 % SUCCESSION XANODYNE ANNOUNCES : 0.82 % more than few : 0.41 % few days MORE : 0.41 % days MORE DuetDHA : 0.41 % than few days : 0.41 % analgesia more than : 0.41 % require opioid analgesia : 0.41 % opioid analgesia more : 0.41 % who require opioid : 0.41 % morphine tablet indicated : 0.41 % adults years or : 0.41 % years or older : 0.41 % or older MORE : 0.41 % older MORE Oramorph : 0.41 % pain adults years : 0.41 % indicated mild moderate : 0.41 % NSAID ProSorb technology : 0.41 % ProSorb technology indicated : 0.41 % technology indicated mild : 0.41 % MORE Oramorph SR : 0.41 % Oramorph SR Oramorph : 0.41 % tablet indicated pain : 0.41 % indicated pain patients : 0.41 % pain patients who : 0.41 % MORE DuetDHA DuetDHA : 0.41 % release morphine tablet : 0.41 % SR Oramorph sustained : 0.41 % Oramorph sustained release : 0.41 % sustained release morphine : 0.41 % patients who require : 0.41 % right amounts key : 0.41 % News Announcements XANODYNE : 0.41 % Announcements XANODYNE ANNOUNCES : 0.41 % Welcome Xanodyne Recently : 0.41 % MORE HOME PRIVACY : 0.41 % tolerated MORE HOME : 0.41 % be well tolerated : 0.41 % well tolerated MORE : 0.41 % Xanodyne Recently Approved : 0.41 % Recently Approved Developing : 0.41 % Oramorph SR DuetDHA : 0.41 % SR DuetDHA DuetDHA : 0.41 % Highlights Oramorph SR : 0.41 % Product Highlights Oramorph : 0.41 % Approved Developing Product : 0.41 % Developing Product Highlights : 0.41 % designed be well : 0.41 % minerals designed be : 0.41 % acids prescription prenatal : 0.41 % prescription prenatal vitamin : 0.41 % fatty acids prescription : 0.41 % omega fatty acids : 0.41 % Ferrazone enteric-coated omega : 0.41 % enteric-coated omega fatty : 0.41 % prenatal vitamin that : 0.41 % vitamin that provides : 0.41 % key vitamins minerals : 0.41 % vitamins minerals designed : 0.41 % amounts key vitamins : 0.41 % capsule NSAID ProSorb : 0.41 % that provides right : 0.41 % provides right amounts : 0.41 % DuetDHA Ferrazone enteric-coated : 0.41 % Propoxyphene US market : 0.41 % Voluntarily Withdraw Products : 0.41 % Withdraw Products XANODYNE : 0.41 % Inc Voluntarily Withdraw : 0.41 % Pharmaceuticals Inc Voluntarily : 0.41 % News Announcements Xanodyne : 0.41 % Announcements Xanodyne Pharmaceuticals : 0.41 % Products XANODYNE ANNOUNCES : 0.41 % Welcome Xanodyne Xanodyne : 0.41 % markets pain management : 0.41 % pain management Product : 0.41 % potential markets pain : 0.41 % management market portfolio : 0.41 % Xanodyne Xanodyne Pharmaceuticals : 0.41 % pain management market : 0.41 % Oramorph HOME PRIVACY : 0.41 % Health Oramorph HOME : 0.41 % potential markets Xanodyne's : 0.41 % markets Xanodyne's focus : 0.41 % healthcare market portfolio : 0.41 % women's healthcare market : 0.41 % pain management women's : 0.41 % management women's healthcare : 0.41 % Xanodyne's focus areas : 0.41 % focus areas Zipsor : 0.41 % Management Womens Health : 0.41 % Womens Health Oramorph : 0.41 % Pain Management Womens : 0.41 % Lysteda Pain Management : 0.41 % areas Zipsor Lysteda : 0.41 % Zipsor Lysteda Pain : 0.41 % management Product Withdrawal : 0.41 % Product Withdrawal Xanodyne : 0.41 % acute pain Phase : 0.41 % pain Phase development : 0.41 % treatment acute pain : 0.41 % B treatment acute : 0.41 % Developing XP B : 0.41 % XP B treatment : 0.41 % Phase development Product : 0.41 % development Product Highlights : 0.41 % first liquid filled : 0.41 % liquid filled capsule : 0.41 % Zipsor first liquid : 0.41 % Zipsor Zipsor first : 0.41 % Product Highlights Zipsor : 0.41 % Highlights Zipsor Zipsor : 0.41 % FDA Developing XP : 0.41 % by FDA Developing : 0.41 % US market Recently : 0.41 % market Recently Approved : 0.41 % withdraw Propoxyphene US : 0.41 % agrees withdraw Propoxyphene : 0.41 % Withdrawal Xanodyne agrees : 0.41 % Xanodyne agrees withdraw : 0.41 % Recently Approved Zipsor : 0.41 % Approved Zipsor treatment : 0.41 % adults approved by : 0.41 % approved by FDA : 0.41 % pain adults approved : 0.41 % treatment mild moderate : 0.41 % Zipsor treatment mild : 0.41 % filled capsule NSAID : 0.41 % |
| Total: 267 |
| xanuodyne.com xanodhyne.com uxanodyne.com gxanodyne.com xanodynje.com xanodynex.com xanodyne5.com ckanodyne.com xanodyno.com xanodyen.com xanodayne.com xanodyne4.com xanodynec.com xnodyne.com xanbodyne.com xurnodyne.com xanodcyne.com xanodyhne.com xsanodyne.com xianodyne.com xanopdyne.com lxanodyne.com sxanodyne.com xcanodyne.com xasnodyne.com 8xanodyne.com xunodyne.com xanodyrne.com xanodyne0.com xanodyns.com xeanodyne.com xanodyneg.com wxanodyne.com xanodfyne.com xanofyne.com xanodyme.com xyanodyne.com xaznodyne.com xoanodyne.com xhanodyne.com xanodynev.com 2xanodyne.com xatnodyne.com xanodane.com pxanodyne.com xanoxyne.com xanodyone.com xinodyne.com xaunodyne.com xanodynbe.com xanoodyne.com xarodyne.com xanodyje.com xanhodyne.com xanod7ne.com xanodyneb.com xanoddyne.com xanodiene.com xaynodyne.com xanodyn4e.com anodyne.com xenodyne.com xahodyne.com txanodyne.com xanoydyne.com sanodyne.com xanodyjne.com xanodynd.com xanoedyne.com xanodynse.com xamnodyne.com xanodynwe.com xanodynez.com cxanodyne.com xanodyene.com xanodyne6.com xanodeyne.com xnaodyne.com xan9dyne.com 3xanodyne.com xanodiyne.com xanodoyne.com xanodynai.com xanofdyne.com xaanodyne.com xanody7ne.com xanodiane.com vxanodyne.com xanadyne.com xandoyne.com xanodynie.com xanldyne.com xuanodyne.com xanodynej.com xanodynew.com xanoeyne.com xanrodyne.com 7xanodyne.com xanodyney.com xanodygne.com 5xanodyne.com xzanodyne.com zxanodyne.com canodyne.com xanod6yne.com xanodynw.com xanodene.com ksanodyne.com 6xanodyne.com xainodyne.com xan9odyne.com axanodyne.com rxanodyne.com xandyne.com xanodxyne.com xaqnodyne.com zanodyne.com ixanodyne.com xanodyner.com xanodynep.com xanodyny.com xznodyne.com xanedyne.com mxanodyne.com xanjodyne.com yxanodyne.com 4xanodyne.com xanodne.com xanodyne2.com xaondyne.com xanokdyne.com xanoldyne.com xanodynek.com xanodhne.com wwxanodyne.com xanodyyne.com xanod7yne.com xanodyne.com xanodsyne.com xanmodyne.com xanyodyne.com xaodyne.com xdanodyne.com xanodtyne.com 9xanodyne.com xanodyn3.com xanodynne.com xanodeene.com xanodyneh.com xwanodyne.com xqnodyne.com xaenodyne.com xanocyne.com kxanodyne.com xanodynem.com xanodynme.com danodyne.com xanodybne.com xanodgne.com xannodyne.com xsnodyne.com nxanodyne.com xano0dyne.com xanodytne.com xanoydne.com xankdyne.com xqanodyne.com xanodryne.com fxanodyne.com oxanodyne.com xanoxdyne.com xanodtne.com xajnodyne.com hxanodyne.com xanodynet.com xanlodyne.com xanod6ne.com xanodymne.com xynodyne.com xawnodyne.com xanidyne.com xanodyine.com axnodyne.com xanoudyne.com xan0odyne.com xanodynee.com xabnodyne.com xan0dyne.com xwnodyne.com 1xanodyne.com xanodynye.com xanodyn3e.com xanodnye.com xanodynre.com xanodyne7.com xanodyne8.com xanodone.com qxanodyne.com xanodyni.com xaonodyne.com xahnodyne.com jxanodyne.com xxanodyne.com xanordyne.com xanodyne9.com xanodynae.com xanodynen.com xanodyane.com xanotdyne.com xanodynes.com xanodyned.com xanodyune.com xabodyne.com xanodyneq.com xanodynei.com xanodynoe.com xanodynu.com xanodybe.com xanody6ne.com xarnodyne.com xanodyne1.com xanodgyne.com xanoduyne.com xanodune.com xanodynhe.com xanocdyne.com xanodyneu.com xanodyneo.com xaneodyne.com xaniodyne.com xanodynel.com xanoyne.com xanodynea.com xanodyre.com xanoidyne.com xanodyn4.com xanosdyne.com xanodyhe.com xonodyne.com xanodye.com xanodynr.com xanodine.com xanotyne.com xanpodyne.com xankodyne.com xajodyne.com xanodyna.com xanodynue.com xanaodyne.com xanodyn.com xanudyne.com wwwxanodyne.com xanosyne.com bxanodyne.com xanoadyne.com 0xanodyne.com xanodynef.com xanydyne.com xanodyne3.com xanodynur.com xano9dyne.com xamodyne.com exanodyne.com xanpdyne.com xanodynde.com xanoryne.com dxanodyne.com |